BWAY vs. BVS, AXGN, CBLL, AVNS, IRMD, SIBN, TMCI, KIDS, DCTH, and CLPT
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Bioventus (BVS), AxoGen (AXGN), CeriBell (CBLL), Avanos Medical (AVNS), Iradimed (IRMD), SI-BONE (SIBN), Treace Medical Concepts (TMCI), OrthoPediatrics (KIDS), Delcath Systems (DCTH), and ClearPoint Neuro (CLPT). These companies are all part of the "medical equipment" industry.
BrainsWay vs.
Bioventus (NYSE:BVS) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
BrainsWay received 39 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 66.99% of users gave BrainsWay an outperform vote while only 62.50% of users gave Bioventus an outperform vote.
BrainsWay has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.
BrainsWay has a net margin of 3.88% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat BrainsWay's return on equity.
62.9% of Bioventus shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 32.9% of Bioventus shares are owned by insiders. Comparatively, 19.0% of BrainsWay shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Bioventus has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Bioventus currently has a consensus target price of $15.00, suggesting a potential upside of 49.85%. BrainsWay has a consensus target price of $13.17, suggesting a potential upside of 22.48%. Given Bioventus' higher possible upside, equities analysts clearly believe Bioventus is more favorable than BrainsWay.
In the previous week, Bioventus had 6 more articles in the media than BrainsWay. MarketBeat recorded 6 mentions for Bioventus and 0 mentions for BrainsWay. BrainsWay's average media sentiment score of 1.10 beat Bioventus' score of 0.70 indicating that BrainsWay is being referred to more favorably in the news media.
Summary
BrainsWay beats Bioventus on 11 of the 18 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
This page (NASDAQ:BWAY) was last updated on 2/22/2025 by MarketBeat.com Staff
